肺癌[18F]F-FAPI-42 PET动态显像特征及多参数定量研究:基于uEXPLORER PET/CT的探索性研究
19例初诊肺癌患者行60分钟动态[18F]F-FAPI-42 PET/CT,原发灶摄取呈逐渐升高后平台,甲状腺和胰腺呈快速摄取并持续洗脱;小细胞肺癌较早达平台(11分钟 vs 14分钟)但摄取较低,且Ki和SUVmean低于非小细胞肺癌(P<0.05);不可逆二室模型最适描述肺癌药代动力学。
要点
- 肺癌原发灶[18F]F-FAPI-42摄取逐渐升高后达平台,甲状腺和胰腺呈快速摄取并持续洗脱。
- 小细胞肺癌达平台较早(11分钟 vs 14分钟)但摄取较低,Ki和SUVmean低于非小细胞肺癌(P<0.05)。
- 不可逆二室模型最适描述肺癌动力学,原发灶K比值高于甲状腺和胰腺2-3倍。
核心结论
- 肺癌与甲状腺、胰腺的[18F]F-FAPI-42动态及动力学特征不同。
- 小细胞肺癌与非小细胞肺癌、原发灶与转移灶、较大与较小转移淋巴结之间也存在差异。
- 这些发现为[18F]F-FAPI-42体内药代动力学提供了有价值的信息,可能改善肺癌诊断。
研究设计与样本
- 探索性研究,纳入19例初诊肺癌患者,行60分钟动态[18F]F-FAPI-42 PET/CT。
- 生成肿瘤和正常器官的时间-活性曲线(TAC),计算动力学参数K1、K2、K3、K4、Ki。
- 引入新参数K比值(K1+K3)/(K2+K4)衡量净摄取效率。
- 试验注册号ChiCTR2100045757,2021年4月24日回顾性注册。
主要发现
- 原发灶[18F]F-FAPI-42摄取逐渐升高后达平台,甲状腺和胰腺呈快速摄取并持续洗脱。
- 小细胞肺癌病灶达平台较早(11分钟 vs 14分钟)但摄取较低;平台期小细胞肺癌轻度洗脱而非小细胞肺癌摄取轻度升高。
- 淋巴结和远处转移灶TAC特征与原发灶相似。
- 不可逆二室模型最适描述肺癌药代动力学,可逆二室模型更适合胰腺和甲状腺。
- 原发灶K1、K2、K3、K4低于胰腺和甲状腺(P<0.05),但K比值为其2-3倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore the dynamic and parametric characteristics of [18F]F-FAPI-42 PET/CT in lung cancers. METHODS: Nineteen participants with newly diagnosed lung cancer underwent 60-min dynamic [18F]F-FAPI-42 PET/CT. Time-activity curves (TAC) were generated for tumors and normal organs, with kinetic parameters (K1, K2, K3, K4, Ki) calculated. A new parameter, the K ratio (K1 + K3)/(K2 + K4), was introduced to measure net uptake efficiency. RESULTS: In primary tumor (PT), [18F]F-FAPI-42 uptake showed a gradual increase followed by a plateau, contrasting with organs like the thyroid and pancreas, which showed rapid uptake and continuous washout. Compared to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) lesions reached the plateau earlier (11 min vs. 14 min) but had a lower uptake. During the plateau phase, [18F]F-FAPI-42 demonstrated slight washout in SCLC, whereas its uptake increased slightly in NSCLC. Lymph node and distant metastases exhibited similar TAC profiles to primary tumors. Kinetic modeling revealed that an irreversible two-compartment model (irre-2TCM) best represented the pharmacokinetics of [18F]F-FAPI-42 in lung cancer, whereas re-2TCM was better suited for the pancreas and thyroid. Lower K1, K2, K3 and K4 were observed in PT compared to those in the pancreas and thyroid (P < 0.05), however, the K ratio in PT was found to be 2-3 times higher. SCLC had lower Ki and SUVmean than NSCLC (P < 0.05). Kinetic parameter differences were also observed between PT and metastatic lesions. Larger metastatic lymph nodes exhibited higher K1, Ki, and K ratio than smaller ones. CONCLUSION: Lung cancers exhibit distinct [18F]F-FAPI-42 dynamic and kinetic characteristics compared to the thyroid gland and pancreas. Differences were also observed between SCLC and NSCLC, primary and metastatic lesions, as well as larger versus smaller lesions. These findings provide valuable insights into the in vivo pharmacokinetics of [18F]F-FAPI-42, potentially improving the diagnosis of lung cancer. TRIAL REGISTRATION: ChiCTR2100045757. Registered April 24, 2021 retrospectively registered, http//www.chictr.org.cn.
引用
- Wang L, Pan X, Ye S, et al. [18F]F-FAPI-42 PET dynamic imaging characteristics and multiparametric quantification of lung cancer: an exploratory study using uEXPLORER PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 39760863. doi:10.1007/s00259-024-07064-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。